In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants

T O'Hare, DK Walters, EP Stoffregen, T Jia, PW Manley… - Cancer research, 2005 - AACR
Abstract Imatinib, a Bcr-Abl tyrosine kinase inhibitor, is a highly effective therapy for patients
with chronic myelogenous leukemia (CML). Despite durable responses in most chronic …
被引用次数：1369 相关文章

[引用][C] In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

T O'HARE, DK WALTERS, BJ DRUKER… - Cancer research …, 2005 - pascal-francis.inist.fr
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant
imatinib-resistant Abl kinase domain mutants CNRS Inist Pascal-Francis CNRS Pascal and …

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.

T O'Hare, DK Walters, EP Stoffregen, T Jia… - Cancer …, 2005 - europepmc.org
Imatinib, a Bcr-Abl tyrosine kinase inhibitor, is a highly effective therapy for patients with
chronic myelogenous leukemia (CML). Despite durable responses in most chronic phase …

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

T O'Hare, DK Walters, EP Stoffregen, T Jia… - Cancer …, 2005 - pubmed.ncbi.nlm.nih.gov
Imatinib, a Bcr-Abl tyrosine kinase inhibitor, is a highly effective therapy for patients with
chronic myelogenous leukemia (CML). Despite durable responses in most chronic phase …

In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants

T O'Hare, DK Walters, EP Stoffregen, T Jia… - Cancer …, 2005 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Imatinib, a Bcr-Abl tyrosine kinase inhibitor, is
a highly effective therapy for patients with chronic myelogenous leukemia (CML). Despite …
[PDF] semanticscholar.org

[PDF][PDF] In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants

T O'Hare, DK Walters, EP Stoffregen, T Jia, PW Manley… - pdfs.semanticscholar.org
Abstract Imatinib, a Bcr-Abl tyrosine kinase inhibitor, is a highly effective therapy for patients
with chronic myelogenous leukemia (CML). Despite durable responses in most chronic …
[PDF] academia.edu

[PDF][PDF] In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants

T O'Hare, DK Walters, EP Stoffregen, T Jia, PW Manley… - academia.edu
Abstract Imatinib, a Bcr-Abl tyrosine kinase inhibitor, is a highly effective therapy for patients
with chronic myelogenous leukemia (CML). Despite durable responses in most chronic …

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

T O'Hare, DK Walters, EP Stoffregen, T Jia… - Cancer …, 2005 - ohsu.elsevierpure.com
Abstract Imatinib, a Bcr-Abl tyrosine kinase inhibitor, is a highly effective therapy for patients
with chronic myelogenous leukemia (CML). Despite durable responses in most chronic …

[引用][C] In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

T O'HARE - Cancer Res., 2005 - cir.nii.ac.jp
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant
imatinib-resistant Abl kinase domain mutants | CiNii Research CiNii 国立情報学研究所 学術情報 …